Advertisement
RCKT vs VYGR
Which Stock Would AI Choose? Rocket Pharmaceuticals (RCKT) vs. Voyager Therapeutics (VYGR) Stock Comparison
Key Takeaways
- RCKT is a late-stage gene therapy developer with a recently approved product (Kresladi) and a pivotal cardiovascular program, while VYGR is an earlier-stage platform company targeting neurological diseases.
- Both names carry "Buy"-oriented analyst consensus, but VYGR's average price target implies a notably wider upside spread, reflecting its higher-risk, higher-reward profile.
- RCKT has near-term commercial and regulatory catalysts, whereas VYGR's value hinges on collaboration milestones and early clinical data across its central nervous system (CNS) pipeline.
- Relative performance diverges: RCKT has stabilized near multi-year lows after recent FDA and financing updates, while VYGR has shown more pronounced downside volatility over the past year.
- Cash runways differ meaningfully, with RCKT's capital base bolstered by a Priority Review Voucher sale and a new credit facility, versus VYGR's collaboration-backed balance sheet.
- For deeper coverage of each name, visit RCKT Major News and RCKT Today's Price Move, or VYGR Major News and VYGR Today's Price Move.
- To see how automated strategies are currently positioning across these and other tickers, explore Trending AI Robots.
Introduction
Investors weighing small-cap gene therapy developers often face a common dilemma: choose a company with tangible commercial progress or one with a broader, earlier-stage platform and larger addressable markets. That is the core of this stock comparison. RCKT (Rocket Pharmaceuticals) and VYGR (Voyager Therapeutics) both operate in gene therapy, yet their pipelines, risk profiles, and market positioning diverge sharply. Traders seeking near-term catalysts and momentum may lean one way, while long-term, risk-tolerant investors evaluating platform value may favor the other. This article examines their relative performance, fundamentals, and sentiment to clarify the trade-offs.
RCKT Overview and Recent Performance
Rocket Pharmaceuticals is a late-stage biotechnology company developing genetic therapies for rare, life-threatening diseases. Its most advanced assets target Danon disease, a genetic cardiovascular disorder, and leukocyte adhesion deficiency-I (LAD-I), an ultra-rare immune disorder. In recent months, the company secured U.S. Food and Drug Administration (FDA) accelerated approval for Kresladi, its LAD-I gene therapy, and began patient onboarding preparations. The approval also generated a Rare Pediatric Disease Priority Review Voucher (PRV), which management sold for approximately $180 million to strengthen its balance sheet.
Recent market activity has been shaped by progress on RP-A501, the company's investigational Danon disease therapy. Rocket outlined an FDA-aligned pivotal Phase 2 study plan, and early safety observations from the first patients treated under a modified protocol showed no signs of thrombotic microangiopathy or capillary leak syndrome. The company also secured access to up to $150 million in credit financing to support its cardiovascular pipeline. Analysts have responded with mixed but generally constructive revisions, including an upgrade from Goldman Sachs and a Buy initiation from Needham. The stock trades well below its 52-week high, reflecting lingering investor caution about commercialization timelines and cash consumption.
VYGR Overview and Recent Performance
Voyager Therapeutics is a biotechnology company leveraging its TRACER adeno-associated virus (AAV) capsid discovery platform to develop genetic medicines for neurological diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Friedreich's ataxia. The company also maintains collaboration agreements with larger partners such as Novartis and Neurocrine, which provide milestone and reimbursement revenue while its own pipeline matures.
Over recent weeks and months, VYGR's relative performance has been volatile, with the stock posting a pronounced year-over-year decline despite maintaining a "Strong Buy" consensus among analysts. Near-term focus centers on early-stage programs such as VY7523, an anti-tau antibody for Alzheimer's disease, and VY1706, a tau-silencing gene therapy, both of which carry meaningful clinical and regulatory uncertainty. Quarterly collaboration revenue has been modest, and the company has reported net losses while managing expenses through cost-cutting initiatives. Analysts including H.C. Wainwright, Guggenheim, and Wells Fargo maintain Buy ratings, but insider selling and a lack of near-term clinical catalysts have tempered sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies chosen for their alignment with current market conditions. Tickeron offers hundreds of AI trading bots that monitor thousands of different tickers, but only the best-performing and most suitable strategies earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance history, and the sets of tickers they trade, allowing users to evaluate options ranging from short-term momentum approaches to longer-horizon trend models. Reviewing this selection can help traders understand how data-driven systems are currently assessing names like RCKT and VYGR. To explore the latest featured strategies, visit Trending AI Robots.
Head-to-Head Comparison
The clearest contrast between these two companies lies in their stage of development and market focus. RCKT is closer to generating product revenue, with an approved therapy and a pivotal cardiovascular program backed by recently expanded capital. Its risk is concentrated on execution: converting approval into commercial uptake and completing the Danon disease trial. VYGR, by contrast, is a platform-driven story whose value depends heavily on partnerships and early clinical readouts across a broad CNS pipeline. Its addressable markets are larger, but its timelines are longer and its revenue base is thinner.
On growth drivers, RCKT offers nearer-term catalysts tied to regulatory and commercial milestones, while VYGR's upside rests on collaboration economics and proof-of-concept data. Sector exposure also differs: RCKT is weighted toward rare cardiovascular and hematologic diseases, whereas VYGR is concentrated in neurology. From a risk standpoint, both are pre-profitability and cash-burning, but RCKT's strengthened balance sheet and approved asset provide comparatively more stability than VYGR's earlier-stage, collaboration-dependent profile. Market sentiment for both leans positive among analysts, yet price action suggests investors are demanding a wider margin of safety on VYGR given its longer pathway to sustainable revenue.
Tickeron AI Verdict
Based on observable factors including trend consistency, near-term catalysts, balance-sheet stability, and relative positioning, Tickeron's AI would likely express a modest preference for RCKT in the current environment. Rocket's combination of an approved product, a defined regulatory path for RP-A501, and recently reinforced capital base offers a more stable foundation than Voyager's earlier-stage, data-dependent pipeline. That said, the verdict is probabilistic rather than definitive: VYGR's larger market opportunity and strong analyst support could warrant greater consideration for investors comfortable with elevated volatility and longer time horizons.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a Buy and VYGR is a Hold.
RCKT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RCKT turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 43 of 50 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RCKT as a result. In 61 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 201 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 58 cases where RCKT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.725) is normal, around the industry mean (2.788). P/E Ratio (-15.219) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VYGR's RSI Oscillator ascends from oversold territory
The RSI Indicator for VYGR moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 25 of the 28 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +5.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.687) is normal, around the industry mean (2.788). P/E Ratio (-0.950) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 98 | |
PRICE GROWTH RATING 1..100 | 72 | 86 | |
P/E GROWTH RATING 1..100 | 15 | 11 | |
SEASONALITY SCORE 1..100 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (10) in the Biotechnology industry is somewhat better than the same rating for VYGR (49). This means that RCKT’s stock grew somewhat faster than VYGR’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VYGR (100). This means that RCKT’s stock grew similarly to VYGR’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as VYGR (98). This means that RCKT’s stock grew similarly to VYGR’s over the last 12 months.
RCKT's Price Growth Rating (72) in the Biotechnology industry is in the same range as VYGR (86). This means that RCKT’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's P/E Growth Rating (11) in the Biotechnology industry is in the same range as RCKT (15). This means that VYGR’s stock grew similarly to RCKT’s over the last 12 months.
| RCKT | VYGR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 76% | N/A |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 84% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 83% |
| Declines ODDS (%) | 8 days ago 87% | 8 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RCKT’s FA Score shows that 2 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- RCKT’s FA Score: 2 green, 3 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RCKT’s TA Score shows that 5 TA indicator(s) are bullish while VYGR’s TA Score has 5 bullish TA indicator(s).
- RCKT’s TA Score: 5 bullish, 3 bearish.
- VYGR’s TA Score: 5 bullish, 2 bearish.
Price Growth
RCKT (@Biotechnology) experienced а -4.13% price change this week, while VYGR (@Biotechnology) price change was -2.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -5.53%. For the same industry, the average monthly price growth was -13.89%, and the average quarterly price growth was -21.23%.
Reported Earning Dates
RCKT is expected to report earnings on Mar 01, 2027.
VYGR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-5.53% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VYGR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with EDIT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To VYGR | 1D Price Change % | ||
|---|---|---|---|---|
| VYGR | 100% | -8.02% | ||
| EDIT - VYGR | 60% Loosely correlated | -6.25% | ||
| RCKT - VYGR | 55% Loosely correlated | -6.70% | ||
| DYN - VYGR | 52% Loosely correlated | -6.36% | ||
| MGTX - VYGR | 50% Loosely correlated | -9.66% | ||
| SLDB - VYGR | 50% Loosely correlated | -5.21% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HBR | 9.57 | N/A | N/A |
| CANARY CAPITAL GROUP | |||
| DHY | 16.59 | -0.21 | -1.25% |
| UBS Asset Management High Yield Credit Fund | |||
| ESGD | 101.93 | -3.08 | -2.93% |
| iShares ESG Aware MSCI EAFE ETF (ESGD) | |||
| HFEQ | 21.96 | -0.97 | -4.25% |
| Unlimited HFEQ Equity Long/Short ETF (HFEQ) | |||
| QJUN | 31.24 | -1.48 | -4.52% |
| FT Vest Nasdaq-100 Buffer ETF - June (QJUN) | |||